|Articles|February 19, 2016

What Lies Ahead 2016

Author(s)DIA

What Lies Ahead 2016

DIA’s exclusive annual survey catalogs, ranks, and describes trends to watch in biopharmaceutical, device, and related research, development, and regulation, from expert global and regional perspectives, in the year ahead.

Read the article here.

Lead with insight with the Pharmaceutical Executive newsletter, featuring strategic analysis, leadership trends, and market intelligence for biopharma decision-makers.

What Lies Ahead 2016

Related Content

EMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval

The New Healthy Aging Imperative and What It Means for Pharma

Reading Between the Lines: Closing the T1D Misdiagnosis Gap

Pharmaceutical Executive Daily: FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer

Beyond the Strip: Las Vegas Has a New Kind of Venture in Mind

Trending on PharmExec

EMA’s CHMP Recommends Eli Lilly’s Jaypirca for Approval

Reading Between the Lines: Closing the T1D Misdiagnosis Gap

Pharmaceutical Executive Daily: FDA Clears Trodelvy for First-Line Metastatic Triple-Negative Breast Cancer

The Rise of Direct-to-Patient Models in Pharma: Opportunities and Risks in Bypassing Traditional Distribution Channels

Novartis Announces $105 Million Collaborative Agreement with Antares Therapeutics